Veru (VERU) is Top Pick, Little Doubt in EUA for sabizabulin - Oppenheimer Bullish on Shares Ahead of FDA Decision
Tweet Send to a Friend
(Updated - July 11, 2022 7:15 AM EDT)Oppenheimer analyst Leland Gershell reiterated an Outperform rating and $36.00 price target on ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
